India Pharma Outlook Team | Friday, 26 June 2026
Alembic Pharma has gained entry into the USD 27 million US flu drug market after receiving USFDA approval for its generic flu drug, Oseltamivir Phosphate for Oral Suspension.
The latest USFDA approval allows Alembic Pharma to market the medicine in the United States for treating influenza A and B in patients as young as two weeks old. The approval also strengthens the company's growing presence in the US generics business while expanding its portfolio of respiratory medicines.
The approved product is the generic version of Roche's widely used generic Tamiflu oral suspension. It is available in a strength of 6 mg/mL and is used to treat acute, uncomplicated influenza A and B when symptoms begin within 48 hours. The medicine is also approved to prevent influenza in patients aged one year and above.
The latest USFDA approval gives Alembic Pharma access to a US market valued at around USD 27 million, based on IQVIA data for the 12 months ending March 2026.
The approval covers:
The approval is expected to strengthen the company's US product portfolio, where demand for affordable generic medicines continues to grow.
Also Read: How Digital Maturity is Powering Pharma's GMP Evolution
With this latest clearance, Alembic Pharma now has a total of 243 ANDA approvals from the USFDA. These include:
The company has been steadily adding products to its US portfolio as it focuses on expanding its presence in one of the world's largest pharmaceutical markets.
Earlier this month, Alembic Pharma also received tentative approval for a generic version of Binimetinib, a medicine used in cancer treatment. The latest USFDA approval adds another product to its pipeline and reflects its continued focus on regulated markets.
The new USFDA approval comes at a time when Alembic Pharma is reporting healthy financial growth.
For the quarter ended March 31, 2026, the company posted a consolidated net profit of Rs 202.7 crore, up 29 percent from the same period last year. Revenue also increased across key business segments, supported by domestic and international operations.
The latest approval is expected to further strengthen the company's US business by adding another commercial product to its portfolio. While the addressable market for the product is relatively modest at USD 27 million, it provides another revenue opportunity and reinforces Alembic Pharma's strategy of expanding its presence through high-quality generic medicines.
As competition in the US generic pharmaceutical market remains strong, continued USFDA approval for new products will play a key role in helping Alembic Pharma grow its international business and diversify its revenue base.
Alembic Pharma is one of India's leading pharmaceutical companies with a presence in over 75 countries. The company develops, manufactures, and markets generic medicines across therapeutic segments while maintaining a strong focus on regulated markets such as the United States.
.jpg)
